CN109906271A - 编码Cas9核酸酶的核酸的饮食控制的表达及其用途 - Google Patents

编码Cas9核酸酶的核酸的饮食控制的表达及其用途 Download PDF

Info

Publication number
CN109906271A
CN109906271A CN201780045274.4A CN201780045274A CN109906271A CN 109906271 A CN109906271 A CN 109906271A CN 201780045274 A CN201780045274 A CN 201780045274A CN 109906271 A CN109906271 A CN 109906271A
Authority
CN
China
Prior art keywords
nucleic acid
disease
cell
expression
cas9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045274.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·拉瓦萨德
J·马莱特
C·瑟格拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA, Institut du Cerveau et de La Moelle Epiniere ICM filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN202211117939.7A priority Critical patent/CN116064534A/zh
Publication of CN109906271A publication Critical patent/CN109906271A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
CN201780045274.4A 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途 Pending CN109906271A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211117939.7A CN116064534A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172964 2016-06-03
EPEP16172964 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211117939.7A Division CN116064534A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Publications (1)

Publication Number Publication Date
CN109906271A true CN109906271A (zh) 2019-06-18

Family

ID=56148119

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780045274.4A Pending CN109906271A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途
CN202211117939.7A Pending CN116064534A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211117939.7A Pending CN116064534A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Country Status (11)

Country Link
US (2) US20190185832A1 (https=)
JP (2) JP7436145B2 (https=)
KR (1) KR102317622B1 (https=)
CN (2) CN109906271A (https=)
AU (1) AU2017275769B2 (https=)
BR (1) BR112018074930A2 (https=)
CA (1) CA3025591A1 (https=)
IL (1) IL263291B2 (https=)
RU (1) RU2771383C2 (https=)
SG (1) SG11201810772XA (https=)
WO (1) WO2017207797A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114058689A (zh) * 2020-07-30 2022-02-18 南京市妇幼保健院 一种基因突变检测试剂盒及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314475A1 (en) * 2018-08-01 2021-02-18 The Regents Of The University Of Colorado A Body Corporate Programmable designer therapeutic fusogenic secreted gectosome vesicles for macromolecule delivery and genome modification
CN112442528B (zh) * 2019-08-30 2022-08-12 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
JP2025523643A (ja) * 2022-07-05 2025-07-23 ニュートリセラジェン 細胞免疫療法における使用のためのヒトｔまたはｎｋ細胞における導入遺伝子の発現の制御
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) * 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof
CN105142669A (zh) * 2012-12-06 2015-12-09 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) * 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof
CN105142669A (zh) * 2012-12-06 2015-12-09 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GORI JL ET AL: "Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy", 《HUMAN GENE THERAPY》 *
韩勇等: "新型基因组编辑技术研究进展", 《动物医学进展》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114058689A (zh) * 2020-07-30 2022-02-18 南京市妇幼保健院 一种基因突变检测试剂盒及其应用

Also Published As

Publication number Publication date
SG11201810772XA (en) 2018-12-28
AU2017275769A1 (en) 2018-12-20
JP2022133441A (ja) 2022-09-13
RU2018142174A3 (https=) 2020-09-30
US20190185832A1 (en) 2019-06-20
IL263291B1 (en) 2023-03-01
IL263291B2 (en) 2023-07-01
RU2771383C2 (ru) 2022-05-04
AU2017275769B2 (en) 2023-04-13
CN116064534A (zh) 2023-05-05
IL263291A (en) 2018-12-31
JP7436145B2 (ja) 2024-02-21
JP2019517262A (ja) 2019-06-24
KR102317622B1 (ko) 2021-10-26
BR112018074930A2 (pt) 2019-03-12
KR20190031230A (ko) 2019-03-25
WO2017207797A1 (en) 2017-12-07
CA3025591A1 (en) 2017-12-07
US20230313161A1 (en) 2023-10-05
RU2018142174A (ru) 2020-07-10

Similar Documents

Publication Publication Date Title
CN109906271A (zh) 编码Cas9核酸酶的核酸的饮食控制的表达及其用途
Schaefer et al. A phase 2 study of vorinostat in acute myeloid leukemia
ES2886480T3 (es) Métodos y composiciones para el tratamiento guiado por ARN de una infección por VIH
ES2937245T3 (es) ARN que contiene nucleósidos modificados y métodos de uso del mismo
ES2769129T3 (es) Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
CN109640946A (zh) 通过基因编辑策略进行hiv-1的负反馈调节
US20210254056A1 (en) Identification and targeted modulation of gene signaling networks
JP2022023099A (ja) 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去
JP2020510439A (ja) シトシンからグアニンへの塩基編集因子
CN109415728A (zh) 逆转录病毒核酸序列的切除
Meyn et al. Biochemical modulation of radiation-induced apoptosis in murine lymphoma cells
Yenari et al. Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors
Neschadim et al. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer
US20240401047A1 (en) Trem compositions and methods of use
Truby et al. A zinc finger transcription factor enables social behaviors while controlling transposable elements and immune response in prefrontal cortex
Freeman The multiple roles which cell division can play in the localization of developmental potential
US20250283036A1 (en) Engineering b cell-based protein factories to treat serious diseases
McKenna et al. Molecular mechanisms of programmed cell death
Lu et al. Autophagy occurs within an hour of adenosine triphosphate treatment after nerve cell damage: the neuroprotective effects of adenosine triphosphate against apoptosis
US20210060138A1 (en) CRISPR and LASER ART Eliminates HIV
Irla et al. ZAP-70 restoration in mice by in vivo thymic electroporation
Boulis et al. Regulated neuronal neuromodulation via spinal cord expression of the gene for the inwardly rectifying potassium channel 2.1 (Kir2. 1)
Sharma et al. Exploring the role of cAMP in gabapentin-mediated pain attenuating effects in chronic constriction injury model in rats
EP3464574A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
JP4417273B2 (ja) 精子活性化剤および精子不活性化剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination